StockWatch
·

Paras Healthcare Ltd Q2 FY27 Results

PARASHLTHQ2 FY27 Results
Filing
Result:Steady· Market: Crashed

Outlook: Optimistic · Guidance: None

MetricValue (₹ Cr)
Revenue510.89
Total Income517.35
Expenditure463.13
PBT54.22
Net Profit40.35
OPM23.52%
NPM7.80%
EPS4.00
View full financials

Hospital-sector OPM of 23.5% and NPM of 7.8% are in line with healthy peer margins, but with no YoY comparison available there's no evidence of standout core growth to justify a higher band.

PARAS HEALTHCARE · Q2 FY27 · THE VERDICT

Profit surges while working capital flows backward

Q2 PAT jumped 225% YoY to ₹40.4 Cr on genuine operational leverage, but new hospital empanelments have extended collection cycles. The real question is whether incoming bed capacity sustains this margin inflection or gets pressured by cash collection timing.

13 Nov 2026 · 6 min read
Reported PAT

₹40.3 Cr

+225% YoY (₹12.4 Cr prior)

Operating EBITDA

₹120 Cr

+47% YoY, 23.5% margin

Revenue

₹511 Cr

+23% YoY, organic growth

Working capital swing

₹172 Cr drag

DSO 79→92 days (H1)

Paras Healthcare delivered a genuine profit inflection in Q2 FY27, not through accounting magic but through operational leverage: occupancy recovered 1,400 bps YoY, emerging hospitals (Ranchi, Udaipur) posted 110.9% EBITDA growth, and new hospitals (Kanpur, Srinagar) flipped from heavy losses to mid-teens profitability. Yet the earnings call surfaced a secondary tension—the same new hospital ramps that drove profit higher also extended the company's collection cycle, with DSO jumping to 92 days and negative working capital absorption reaching ₹172 Cr in H1. Cash and profit are diverging, and management's confidence that this normalizes hinges on payor mix improvement in tier-2/3 markets where collections are structurally slower.

Claims vs. what holds up

Management's on-call assertions graded against delivered results

Q2 revenue ₹511 Cr, growth 23% YoY

Supported

Delivered: ₹510.9 Cr. Matches precisely.

Q2 PAT ₹40.3 Cr, 3.3x last year

Supported

Delivered: ₹40.4 Cr. Prior year Q2 PAT ₹12.4 Cr = 3.26x. Verified.

Operating EBITDA margin 23.5%, up 390 bps

Supported

₹120 Cr / ₹511 Cr = 23.5%. Prior year 18.1% + 390 bps = 23.5%. Correct.

Emerging hospital EBITDA growth 110.9% in H1

Supported

Ranchi + Udaipur cohort H1 contribution material; Ranchi 25.8% EBITDA margin in Q2. Growth figure verified.

New hospitals (Srinagar/Kanpur) showed 139-147% revenue growth

Supported

Q2: 139% YoY, H1: 147% YoY stated explicitly. EBITDA margin -22.8% to +15.6% in Kanpur verified.

What changed on this call

  • Emerging hospital profitability inflected ahead of schedule—Ranchi now at 25.8% margin (Q2) vs. cohort average 18.3% (H1). Was tracking 12.4% prior year.

  • New hospital ramp-up playbook validated in real time—Kanpur occupancy 78.4% and EBITDA margin +15.6% (Q2) vs. -22.8% prior year. Srinagar also turned profitable.

  • Working capital cycle shifted materially—DSO extended from 79 to 92 days in H1. ₹172 Cr negative impact, driven by new hospital empanelments and government scheme mix.

  • Government scheme dependency flagged as material risk—Udaipur hospital revenues suspended during Rajasthan scheme review (temporary). 44% of H1 payor mix from government schemes & PSUs.

  • No formal numeric guidance provided—CFO explicitly stated 'no guidance as such.' Playbook target (mid-20s blended EBITDA) is aspirational, not committed.

Where the profit came from (organic waterfall)

Unlike the template's typical MTM-gain reconciliation, Paras's profit jump is entirely organic. Revenue grew 23% YoY (+₹83 Cr baseline). Occupancy recovery (+1,400 bps) and case mix improvement (lower ALOS, higher acuity) drove EBITDA to ₹120 Cr (+47% YoY). Finance costs fell post-IPO (debt repayment ₹375 Cr from ₹500 Cr net raise), contributing ~₹10-15 Cr to profit. Tax normalization helped. No other-income gains or exceptional items cited. The PAT expansion to ₹40.3 Cr (+225% YoY) traces directly to operational leverage and lower financing burden—genuine performance, not an accounting artifact.

We will be having more beds coming up in Gurgaon 2, as well as Ludhiana over the next 12-18 months, as we have said that 300 beds are coming up in Gurgaon and 500 beds for Ludhiana in the following year.

The bull-bear ledger

What favors the bulls
  • Operating leverage is real. Margins expanded 390 bps on just 23% revenue growth—a 1.7x operational multiplier, driven by fixed-cost absorption and occupancy gains.

  • Emerging hospital inflection (110.9% EBITDA growth, Ranchi at 25.8%) validates the geographic-expansion playbook ahead of schedule.

  • New hospital ramp is repeatable—Kanpur went from 22.7% occupancy (prior year) to 78.4% (H1), from -₹50+ Cr EBITDA to positive. Srinagar following a similar path.

  • Balance sheet strengthened post-IPO: gross debt ₹979 Cr → net debt ₹143 Cr pro forma (after ₹375 Cr repayment). Capacity for further expansion.

  • ALOS at 2.8–2.9 days among the lowest listed operators. Surgical case mix + specialty depth = efficiency moat in tier-2 markets.

What bears worry about
  • Working capital absorption (₹172 Cr H1, DSO 79→92 days) offsets cash generation. If new hospital empanelments don't improve payor mix quickly, cash drag persists.

  • Government scheme concentration (44% of payor mix in H1) introduces regulatory risk. Udaipur scheme review already suspended revenue temporarily; state-level reviews could recur.

  • New hospital execution uncertainty—Kanpur and Srinagar occupancy and profitability must sustain as bed additions continue. Any clinical staffing or market maturation delays could reset margins.

  • Medical talent scarcity in tier-2/3 cities (explicitly cited for Darbhanga) constrains specialist availability and case mix improvement speed.

  • Mature hospital revenue growth slowing—H1 mature cluster +9.1% YoY vs. +25% group. Occupancy at 76.5% has limited headroom without capacity additions (Golf Course Extension underway but not yet operational).

  • No formal guidance. Investors forced to model from disclosed trends; management playbook (mid-20s EBITDA target) is aspirational, not a commitment.

Risks, ranked by how much they should concern a holder

What could derail the bull case, in order of severity

Government scheme dependency and regulatory disruption

Medium-High

44% of H1 payor mix from government schemes & PSUs. Udaipur scheme review already suspended revenue temporarily. State-level policy changes (reimbursement rates, empanelment rules) could suppress volumes or margins across the cohort. This is not a one-off; it's a structural concentration risk in every tier-2 market Paras operates.

Working capital normalization fails to materialize

Medium-High

DSO jumped from 79 to 92 days (H1) and is the largest drag on cash conversion. If new hospital empanelments don't shift payor mix toward private insurance/cash, DSO could stay elevated or worsen. A 13-day DSO extension on ₹500 Cr+ revenue base means ₹20-25 Cr in perpetual working capital freeze. Profit growth gets hollowed by cash drag.

New hospital ramp-up execution slips (Kanpur/Srinagar)

Medium

Kanpur and Srinagar are proving grounds for the scalable playbook. Occupancy at 78.4% and 60.4% respectively (H1) is strong but not mature-hospital stable (76.5% group). Any macro slowdown, clinical staffing delays, or case mix disappointment could reset these margins. Gurgaon Golf Course Extension and Ludhiana timelines are also unproven.

Medical talent scarcity constrains case mix improvement

Medium

Management explicitly cited difficulty recruiting tertiary/quaternary specialists in tier-2 cities (e.g., Darbhanga). Case mix improvement (higher ALOS surgical cases, robotic surgery, transplants) depends on specialist availability. If talent remains scarce, occupancy gains won't translate to margin gains as expected.

Mature hospital occupancy plateau limits growth

Low

Mature cluster (Gurgaon, Patna, Panchkula, Darbhanga) at 76.5% occupancy with only +9.1% revenue growth (H1 YoY). Without Gurgaon Golf Course Extension capacity, revenue growth will stall in the mature cohort. Impact is delayed but real if capex execution slips.

What to watch next

Three concrete signals for the next 2–3 quarters
  • 1 · DSO and working capital normalization path (Q3-Q4 FY27)

    Is DSO tracking back toward 85–88 days? If new hospital case mix improves and payor mix shifts toward private/insurance, ₹172 Cr negative working capital should reverse partially. Watch H1→H2 DSO trend and management's commentary on collections velocity. If DSO stays >90 days or rises further, the cash-conversion thesis is broken.

  • 2 · Gurgaon Golf Course Extension operationalization (Q3-Q4 FY27 / FY28)

    When do the 300 incremental beds come online? At what occupancy and margin? This unlocks mature hospital revenue growth from the current 9% to double-digit %. Timely opening suggests execution discipline; delays suggest capex/clinical staffing friction.

  • 3 · Udaipur government scheme restart and Kanpur/Srinagar occupancy sustainability (Q3-Q4 FY27)

    Does the Rajasthan scheme review conclude favorably, unlocking the 30–40% of Udaipur revenue management said was suspended? Simultaneously, as Kanpur beds operationalize (200–250 still to open), do occupancy and EBITDA margins hold or compress? If both normalize as expected, emerging cohort profitability inflection will prove durable. If either disappoints, profit growth will decelerate sharply.

The honest read

Paras Healthcare delivered a genuine operational quarter—not a blowout in the headline-accounting sense, but a step-change in the operational playbook. Q2 revenue of ₹511 Cr (+23% YoY) on a 23.5% operating margin represents the beginning of sustainable mid-20s EBITDA growth, enabled by occupancy recovery, emerging hospital profitability inflection (110.9% EBITDA growth), and new hospital maturation. PAT inflation to ₹40.3 Cr (+225% YoY) is real leverage, not a one-time item.

Yet the call surface a secondary story that holds equal weight—working capital absorption of ₹172 Cr in H1, driven by DSO extension from 79 to 92 days. This is not a timing issue that resolves in Q3; it reflects structural payor-mix and empanelment realities in tier-2 India. Until new hospitals shift toward private payers and case mix improves, cash conversion will lag profit growth. For a holder, this means watching three things: DSO normalization (the cash proxy), Gurgaon Golf Course operationalization (the mature-cohort circuit breaker), and Udaipur scheme restart + Kanpur sustainability (the emerging/new cohort proof points).

If management delivers on bed additions and occupancy/case mix inflection, the emerging hospital playbook becomes repeatable at scale, and mid-20s blended EBITDA margins are achievable. If execution slips on any of these fronts—or if government scheme risk recurs—profit growth will be offset by working capital drag and capex timing uncertainty. The quarter itself is solid and execution is credible. The stock's next move is a cash-conversion story, not a profit-growth story.

Informational and educational content only. Not investment advice.